Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.

Author: KeitelVerena, KloseSilke, KrauseAndreas, KreisslMichael C, MüllerChristian, VeneritoMarino

Paper Details 
Original Abstract of the Article :
Pancreatic neuroendocrine tumors (pNETs) are rare entities representing 1% to 3% of all malignant pancreatic neoplasms. Current guidelines recommend a combination of streptozocin (STZ) and 5-fluorouracil (5-FU) for patients with metastatic well-differentiated pNETs requiring systemic therapy. The hi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797514/

データ提供:米国国立医学図書館(NLM)

Navigating the Long-Term Landscape of Pancreatic Neuroendocrine Tumors (pNETs) Treatment

Pancreatic neuroendocrine tumors (pNETs) are like hidden oases in the vast desert of cancer. This study explores the long-term effectiveness of a combination chemotherapy regimen, streptozocin and 5-fluorouracil, for treating these rare tumors. It's like a seasoned explorer charting a course through uncharted territory, seeking to understand the long-term effects of this treatment approach.

Long-Term Treatment of Pancreatic Neuroendocrine Tumors: A Case Series

While previous studies have shown promise for this combination therapy, this research delves deeper into its long-term efficacy and safety. It presents a case series examining the effects of this treatment over an extended period, providing valuable insights into its long-term potential.

Pancreatic Neuroendocrine Tumor Treatment: A Journey Towards Improved Outcomes

This study serves as a valuable guide for clinicians treating patients with metastatic pNETs. It provides evidence-based insights into the long-term efficacy and safety of a commonly used chemotherapy regimen, aiding in informed decision-making and potentially improving patient outcomes.

Dr. Camel's Conclusion

Like a camel navigating a treacherous desert landscape, treating pancreatic neuroendocrine tumors requires a careful and strategic approach. This study offers valuable insights into the long-term effects of a commonly used chemotherapy regimen, helping doctors chart a course towards improved outcomes for their patients.
Date :
  1. Date Completed 2022-03-04
  2. Date Revised 2023-01-03
Further Info :

Pubmed ID

35089197

DOI: Digital Object Identifier

PMC8797514

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.